Inflammatory landscape in Xeroderma pigmentosum patients with cutaneous melanoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 08 2022
16 08 2022
Historique:
received:
25
03
2022
accepted:
02
08
2022
entrez:
16
8
2022
pubmed:
17
8
2022
medline:
19
8
2022
Statut:
epublish
Résumé
Xeroderma pigmentosum (XP) is a DNA repair disease that predisposes to early skin cancers as cutaneous melanoma. Melanoma microenvironment contains inflammatory mediators, which would be interesting biomarkers for the prognosis or for the identification of novel therapeutic targets. We used a PCR array to evaluate the transcriptional pattern of 84 inflammatory genes in melanoma tumors obtained from XP patients (XP-Mel) and in sporadic melanoma (SP-Mel) compared to healthy skin. Commonly expressed inflammatory genes were further explored via GTEx and GEPIA databases. The differentially expressed inflammatory genes in XP were compared to their expression in skin exposed to UVs, and evaluated on the basis of the overall survival outcomes of patients with melanoma. Monocyte subsets of patients with SP-Mel, XP and healthy donors were also assessed. PCR array data revealed that 34 inflammatory genes were under-expressed in XP-Mel compared to SP-Mel. Differentially expressed genes that were common in XP-Mel and SP-Mel were correlated with the transcriptomic datasets from GEPIA and GTEx and highlighted the implication of KLK1 and IL8 in the tumorigenesis. We showed also that in XP-Mel tumors, there was an overexpression of KLK6 and KLK10 genes, which seems to be associated with a bad survival rate. As for the innate immunity, we observed a decrease of intermediate monocytes in patients with SP-Mel and in XP. We highlight an alteration in the immune response in XP patients. We identified candidate biomarkers involved in the tumorigenesis, and in the survival of patients with melanoma. Intermediate monocyte's in patients at risk could be a prognostic biomarker for melanoma outcome.
Identifiants
pubmed: 35974070
doi: 10.1038/s41598-022-17928-z
pii: 10.1038/s41598-022-17928-z
pmc: PMC9381529
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13854Informations de copyright
© 2022. The Author(s).
Références
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Trends Immunol. 2014 Sep;35(9):429-35
pubmed: 25023467
Immunity. 2015 Feb 17;42(2):332-343
pubmed: 25692705
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Cancer Cell. 2020 Aug 10;38(2):167-197
pubmed: 32649885
Immunol Res. 2012 Sep;53(1-3):41-57
pubmed: 22430559
J Biol Chem. 2007 Feb 9;282(6):3640-52
pubmed: 17158887
Orphanet J Rare Dis. 2022 Mar 4;17(1):104
pubmed: 35246173
Mech Ageing Dev. 2021 Sep;198:111525
pubmed: 34166688
PLoS One. 2016 Sep 19;11(9):e0163054
pubmed: 27643989
J Invest Dermatol. 2001 Nov;117(5):1151-5
pubmed: 11710926
Cell Physiol Biochem. 2012;29(5-6):667-74
pubmed: 22613967
Biol Chem. 2006 Jun;387(6):643-52
pubmed: 16800725
Adv Enzyme Regul. 1994;34:381-95
pubmed: 7942283
J Clin Immunol. 2018 Jan;38(1):35-44
pubmed: 29098565
DNA Repair (Amst). 2008 May 3;7(5):744-50
pubmed: 18329345
J Invest Dermatol. 2021 Apr;141(4S):976-984
pubmed: 33436302
EPMA J. 2016 Dec 8;7:24
pubmed: 27980697
Arch Dermatol. 1987 Feb;123(2):241-50
pubmed: 3545087
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Indian J Ophthalmol. 2019 Feb;67(2):308-309
pubmed: 30672507
Pediatr Blood Cancer. 2017 Nov;64(11):
pubmed: 28557197
J Mol Signal. 2016 May 05;11:2
pubmed: 31051015
Nat Rev Cancer. 2001 Oct;1(1):22-33
pubmed: 11900249
Eur J Cancer. 1995 Jun;31A(6):924-8
pubmed: 7646923
Clin Exp Immunol. 1992 Jun;88(3):376-82
pubmed: 1535035
Trends Immunol. 2016 Jun;37(6):364-374
pubmed: 27151281
Head Neck. 2019 Jun;41(6):1880-1888
pubmed: 30636187
Immunobiology. 2012 Dec;217(12):1273-84
pubmed: 22898391
Mol Med Rep. 2020 May;21(5):2063-2072
pubmed: 32323762
Neurogastroenterol Motil. 2018 Dec;30(12):e13468
pubmed: 30230134
Front Genet. 2019 Feb 14;10:111
pubmed: 30838033
Anticancer Res. 2018 Feb;38(2):1153-1158
pubmed: 29374752
Anticancer Res. 2004 Jan-Feb;24(1):43-51
pubmed: 15015574
Arthritis Rheumatol. 2020 Jan;72(1):100-113
pubmed: 31390156
Front Pharmacol. 2017 Aug 25;8:563
pubmed: 28970795
Ophthalmology. 2018 Aug;125(8):1139-1142
pubmed: 30032793
Immunol Cell Biol. 2001 Dec;79(6):547-68
pubmed: 11903614
Orphanet J Rare Dis. 2011 Nov 01;6:70
pubmed: 22044607
Cancer Res. 2021 May 1;81(9):2545-2555
pubmed: 33574091
J Immunol. 2012 Oct 15;189(8):3789-93
pubmed: 23042723
Clin Immunol. 2021 Apr;225:108677
pubmed: 33476742
Pigment Cell Melanoma Res. 2014 May;27(3):454-64
pubmed: 24483290
J Leukoc Biol. 2019 Aug;106(2):309-322
pubmed: 30776148
Future Oncol. 2010 Jan;6(1):111-6
pubmed: 20021212
J Med Biochem. 2018 Jan 01;37(1):12-20
pubmed: 30581337
Cancer Manag Res. 2020 Sep 28;12:9235-9246
pubmed: 33061614
Br J Dermatol. 2013 Dec;169(6):1279-87
pubmed: 23889214
Br J Dermatol. 2016 Feb;174(2):439-43
pubmed: 26211814
Case Rep Dermatol. 2013 Mar 09;5(1):64-8
pubmed: 23626541
Matrix Biol Plus. 2019 Nov 21;6-7:100019
pubmed: 33543017
J Biol Chem. 2003 May 23;278(21):18767-75
pubmed: 12644471
Clin Biochem. 2020 Mar;77:41-47
pubmed: 31904348
Cancer Immunol Res. 2014 Mar;2(3):241-8
pubmed: 24778320
Int J Dermatol. 2017 Jan;56(1):40-48
pubmed: 27785785
J Clin Invest. 1993 Sep;92(3):1135-42
pubmed: 7690772
Int J Mol Sci. 2017 Aug 19;18(8):
pubmed: 28825631
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5
pubmed: 25918390
Int J Cancer. 2007 Dec 1;121(11):2373-80
pubmed: 17893866
Nat Rev Cancer. 2019 Dec;19(12):698-715
pubmed: 31666715
J Cutan Pathol. 2010 Apr;37(4):452-9
pubmed: 19719835
J Clin Invest. 1989 Sep;84(3):1036-40
pubmed: 2760210
J Exp Med. 2017 Jul 3;214(7):1913-1923
pubmed: 28606987
Haematologica. 2020 Apr;105(4):e144-e146
pubmed: 31439674
J Med Genet. 2011 Mar;48(3):168-76
pubmed: 21097776
Cell Biochem Funct. 2015 Jul;33(5):257-65
pubmed: 26153649
Ann Dermatol Venereol. 2018 Nov;145(11):706-722
pubmed: 30409434
PLoS Pathog. 2018 Dec 6;14(12):e1007353
pubmed: 30522130
J Invest Dermatol. 2013 Jul;133(7):1713-7
pubmed: 23760049
Elife. 2017 Mar 31;6:
pubmed: 28362262
Biochim Biophys Acta. 2013 Oct;1834(10):2176-86
pubmed: 23137658
J Invest Dermatol. 2005 Apr;124(4):778-85
pubmed: 15816836
Trends Biochem Sci. 2018 May;43(5):327-341
pubmed: 29699641
Cancers (Basel). 2010 May 07;2(2):794-808
pubmed: 24281094
J Invest Dermatol. 2002 Jun;118(6):915-22
pubmed: 12060384
Pediatr Dermatol. 1990 Jun;7(2):132-5
pubmed: 2359729
Br J Dermatol. 2017 Jan;176(1):145-158
pubmed: 27442805
Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1548-1558
pubmed: 28596372
Am J Hematol. 2015 Aug;90(8):702-8
pubmed: 25963299
J Proteome Res. 2010 Nov 5;9(11):5557-67
pubmed: 20822092
J Invest Dermatol. 1990 Jan;94(1):94-100
pubmed: 2295840
Clin Exp Immunol. 2000 Jul;121(1):1-7
pubmed: 10886231
Oncol Lett. 2019 May;17(5):4068-4084
pubmed: 30944600
Cancer. 1986 Jul 15;58(2):219-21
pubmed: 2941138
J Invest Dermatol. 2011 Nov;131(11):2281-8
pubmed: 21753781
Front Immunol. 2018 Jul 30;9:1726
pubmed: 30105020
Eur J Biochem. 1998 Apr 15;253(2):485-93
pubmed: 9654101